IgGenix Shares Data on IGNX001 for Peanut Allergy at 2024 ASCIA Conference

IgGenix, Inc., based in South San Francisco, is a pioneering company in the preclinical stage of antibody discovery and development, with a special focus on IgE-mediated diseases. On September 2, 2024, the company presented promising data on its leading candidate, IGNX001, an IgG4 monoclonal antibody therapeutic aimed at treating peanut allergies. These findings were showcased at the 2024 Annual Conference of the Australasian Society of Clinical Immunology and Allergy (ASCIA), held in Adelaide, Australia from September 3-6, 2024.

Key Highlights from the ASCIA Conference

Michael O'Sullivan, MBBS, FRACP, FRCPA, the lead investigator, shared updates on IgGenix's ongoing Phase 1 human clinical trial known as "ACCELERATE Peanut." This study is currently active and in the screening phase, intending to assess the safety and tolerability of IGNX001. The goal of this therapeutic candidate is to provide rapid protection for individuals with peanut allergies.

Derek Croote, PhD, the Chief Technology Officer and co-founder of IgGenix, presented preclinical data demonstrating that IGNX001 offers robust protection against peanut-induced mast cell activation and anaphylaxis in a murine model of peanut allergy. These comprehensive preclinical results were recently published in "The Journal of Allergy and Clinical Immunology."

According to Michael O'Sullivan, Consultant Clinical Immunologist at Fiona Stanley Hospital and Perth Children's Hospital, and Clinical Senior Lecturer at the University of Western Australia, "IGNX001 represents a potentially significant advancement in peanut allergy treatment. This approach leverages cutting-edge research to re-engineer harmful IgE antibodies into IgG4 blocking antibodies. These antibodies bind to allergens without triggering allergic reactions, offering a faster and potentially more effective alternative to existing therapies. This could revolutionize peanut allergy management, reducing the risk of severe reactions and enhancing the quality of life for millions globally."

Detailed Presentations at the Conference

Oral Presentation:
- Title: Accelerating Towards Treatment Options for Adolescents and Adults With Peanut Allergy: Phase 1 Trial of Peanut-Specific IgG4 Antibody Therapeutic (IGNX001)
- Presenter: Michael O'Sullivan, MBBS, FRACP, FRCPA

Poster Presentation:
- Title: Preclinical Activity and GLP Safety Toxicology Data Ahead of Phase 1 Initiation of IGNX001 in Peanut Allergy
- Presenter: Derek Croote, PhD

About IgGenix

IgGenix is a privately held company dedicated to antibody discovery and development, adopting a groundbreaking approach to tackling allergies and atopic diseases. Utilizing their proprietary SEQ SIFTER™ discovery platform, developed from the foundational research of co-founders Stephen Quake, Kari Nadeau, and Derek Croote from Stanford University, IgGenix isolates and re-engineers fully human, high-affinity, allergen-specific antibodies. These antibodies are designed to block and prevent the allergic cascade. By targeting common immunodominant allergens and their significant epitopes across the patient population, the company aims to treat both pediatric and adult patients suffering from food and environmental allergies. This innovative approach holds the promise of preventing life-threatening allergic reactions, potentially saving lives and alleviating the constant fear experienced by millions living with severe allergies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!